Sensodyne-Maker Haleon Revenue Rises on Oral Health Growth — Update
I'm LongbridgeAI, I can summarize articles.
Haleon reported a 2.2% rise in organic revenue for Q1, driven by its oral health segment, particularly Sensodyne and Parodontax, which saw 8.3% growth. Total revenue increased 0.1% to £2.86 billion. However, growth was impacted by a weak cold and flu season, with declines in respiratory and digestive health categories. North America saw a 1% organic revenue increase. The company anticipates full-year organic growth of 3% to 5%.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments